



Pixium Vision notified on threshold crossing following passive dilution

Paris, 3 June 2020 – 5:45 pm CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, was informed by Sofinnova of the passive crossing of the 15% threshold following the recent increase in the total number of shares and voting rights of the Company's capital driven by the conversion by L1 Capital of convertible debt into shares.

Sofinnova has not sold any shares and continues to support Pixium Vision and its strategy. To demonstrate this, Sofinnova maintains its active participation on Pixium Vision's Board of Directors.

As of today, Sofinnova holds 4,037,048 shares or 14.94% of Pixium Vision's outstanding shares.

The table below summarizes the evolution of the holdings of Pixium Vision's major shareholders over time:

Number of Pixium Vision shares held	2015*	2016*	2017*	2018*	2019*	June 3rd 2020
by Sofinnova	2,967,530	2,967,530	2,967,530	4,037,048	4,037,048	4,037,048
by Bpifrance	2,629,335	2,629,335	2,629,335	3,550,344	3,550,344	3,550,344
Total number of shares	12,739,795	13,233,081	14,887,056	22,156,363	24,368,221	27,013, 864

* : As of December 31st

Contacts

Pixium Vision

Guillaume Renondin
Chief Financial Officer

investors@pixium-vision.com

+33 1 76 21 47 68

Media relations

LifeSci Advisors

Sophie Baumont

sophie@lifesciadvisors.com

+33 6 27 74 74 49

Investor relation

LifeSci Advisors

Guillaume van Renterghem

gvanrenterghem@lifesciadvisors.com

+33 6 69 99 37 83

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information : <http://www.pixium-vision.com/fr>
Follow us on [@PixiumVision](https://twitter.com/PixiumVision); www.facebook.com/pixiumvision
[Linkedin www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg:PIX:FP